PMID- 15503319
OWN - NLM
STAT- MEDLINE
DCOM- 20050503
LR  - 20141120
IS  - 1549-3296 (Print)
IS  - 1549-3296 (Linking)
VI  - 71
IP  - 4
DP  - 2004 Dec 15
TI  - In vitro cytocompatibility assessment of beta-tricalcium 
      phosphate/carboxymethyl-chitin composite.
PG  - 635-43
AB  - A novel bioabsorbable bone substitute composed of a beta-tricalcium phosphate 
      (beta-TCP) and a carboxymethyl-chitin (CM-chitin) sodium has been developed. 
      Rabbit tibia defects (4 mm in diameter) were repaired after 4 weeks more 
      effectively by the composite compared with a sham-operation group. To further 
      investigate the biological safety of the components, genotoxicity and 
      carcinogenicity of an extract prepared from the composite were determined using 
      four different in vitro assays. The main extract component was identified as 
      CM-chitin sodium [average molecular weight (Mw) approximately 230 kDa] as 
      determined by Fourier transform infrared spectroscopy and gel permeation 
      chromatography analysis. The concentrations of P and Ca possibly derived from 
      beta-TCP were 17.7 and 37.1 microg/g, respectively, as determined by inductively 
      coupled plasma mass spectroscopy. Both the metabolic activation and nonactivation 
      (-S9) systems of the rat microsome S9 fraction were used to perform a 
      genotoxicity evaluation using the Ames test and chromosome aberration assay on 
      Chinese hamster lung fibroblast cells treated with the extract. In these assays, 
      no genotoxicity was detected with doses < or =5 mg/mL (maximum concentration). 
      The cell transformation assay using BALB/c 3T3 cells and the metabolic 
      cooperation assay with V79 cells both showed negative results for any 
      tumor-promoting activity caused by the extract (approximately 5 mg/mL). These 
      results indicate that the bioabsorbable beta-TCP/CM-chitin composite is a highly 
      biocompatible bone substitute.
FAU - Muramatsu, Kazuaki
AU  - Muramatsu K
AD  - Biochemical Research Section, Bioceram Division, Kyocera Corporation, 10-1 Kawai, 
      Gamo-cho, Gamo-gun, Shiga 529-1595, Japan. kazuaki-muramatsu@kyocera.co.jp
FAU - Nakajima, Madoka
AU  - Nakajima M
FAU - Kikuchi, Masanori
AU  - Kikuchi M
FAU - Shimada, Sawako
AU  - Shimada S
FAU - Sasaki, Kiyoshi
AU  - Sasaki K
FAU - Masuda, Shingo
AU  - Masuda S
FAU - Yoshihara, Yusuke
AU  - Yoshihara Y
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Biomed Mater Res A
JT  - Journal of biomedical materials research. Part A
JID - 101234237
RN  - 0 (Calcium Phosphates)
RN  - 1398-61-4 (Chitin)
RN  - 52519-63-8 (O-(carboxymethyl)chitin)
RN  - K4C08XP666 (tricalcium phosphate)
SB  - IM
MH  - 3T3 Cells
MH  - Animals
MH  - Calcium Phosphates/*chemistry
MH  - Carcinogenicity Tests
MH  - Cell Transformation, Neoplastic/drug effects
MH  - Chitin/*analogs & derivatives/*chemistry
MH  - Chromosome Aberrations/chemically induced
MH  - Cricetinae
MH  - Cricetulus
MH  - In Vitro Techniques
MH  - *Materials Testing
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mutagenicity Tests
MH  - Prostheses and Implants
MH  - Rabbits
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Salmonella/drug effects/genetics
MH  - Spectroscopy, Fourier Transform Infrared
MH  - Tibia/pathology
EDAT- 2004/10/27 09:00
MHDA- 2005/05/04 09:00
CRDT- 2004/10/27 09:00
PHST- 2004/10/27 09:00 [pubmed]
PHST- 2005/05/04 09:00 [medline]
PHST- 2004/10/27 09:00 [entrez]
AID - 10.1002/jbm.a.30197 [doi]
PST - ppublish
SO  - J Biomed Mater Res A. 2004 Dec 15;71(4):635-43. doi: 10.1002/jbm.a.30197.